Capabilities
Technology Development
From Sequence to Vector
Whether starting from a nucleotide sequence, an amino acid sequence, or an early-stage concept, ReiThera transforms innovative ideas into functional viral vectors ready for research, pre-GMP development, or GMP manufacturing.
Our Technology Development Unit combines molecular engineering, proprietary platform technologies, and analytical expertise to support every stage of vector design and seed generation.
Expertise in Viral Vector Engineering & Seed Generation
We design, engineer, optimize, and characterize viral vectors for vaccines and advanced therapies, supporting projects from early R&D through GMP manufacturing.
What we can do for you
Plasmid construction and sequence assembly
Cell Line Development
Our proprietary production cell lines have been specifically developed to support scalable manufacturing across multiple viral vector platforms.
Adenoviral Production
ReiCell35s™
- Large T antigen-free early-passage HEK293 cells
- TetR-mediated transgene repression during production
- Compatible with TetO-engineered adenoviral vectors
- High productivity
ReiCell™
- Large T antigen-free HEK293 production platform
- Optimized for adenoviral manufacturing
AAV Production
ReiCell-AAV™
- Suspension-adapted HEK293 platform
- Optimized for scalable AAV production
- Compatible with proprietary transfection-free technologies
MVA Production
Duck Embryo Fibroblast-derived production platform optimized for MVA manufacturing.
GRAd® Platform Development
ReiThera isolated and developed the GRAd32 gorilla adenovirus, a proprietary vector platform combining:
- Low human seroprevalence
- High productivity
- Strong immunogenicity
- Proven thermostability
The platform has been clinically validated through COVID-19 vaccine development and is currently supporting additional clinical programs.
Advanced genome engineering strategies further optimize:
- Transgene expression
- Vector stability
- Manufacturing performance
MVA Platform Development
Our MVA technology includes:
- Access to the original MVA strain
- Proprietary recombinant seed generation workflow
- Rapid generation of recombinant MVA vectors
- Manufacturing-ready development process
AAV Platform Development
ReiThera has developed proprietary technologies to simplify AAV manufacturing, including:
- Transfection-free production strategies
- HEK293-derived production platforms
- Scalable upstream processes
- Manufacturing-oriented vector design
Custom Analytical Development
Technology Development works in close collaboration with our Analytics group to establish customized analytical strategies supporting:
- Identity
- Purity
- Potency
- Stability
Methods are developed from R&D through GMP transfer, ensuring continuity across the entire product lifecycle.
Innovation Backed by Intellectual Property
Our platform technologies are supported by a growing intellectual property portfolio.
GRAd®
WO2022003083A1
Gorilla adenovirus nucleic acid and amino acid sequences, vectors containing same, and uses thereof.
Granted in Taiwan and Russia, pending in additional jurisdictions.
rAAV Manufacturing
WO2026068629A1
Methods and constructs for recombinant AAV production.
Additional proprietary technologies are currently under development.
The result is an analytical function designed not only to generate data, but to accelerate development, strengthen process understanding, and support successful regulatory outcomes.